.Attributes Medication, Published online: 16 September 2024 doi:10.1038/ s41591-024-03244-8In the observational SCRUM-Japan GOZILA research, after a typical follow-up of 11 months, individuals along with metastatic stomach tumors that received biomarker-matched therapies based upon spreading cyst DNA profiling revealed a higher clinical advantage than those obtaining incomparable treatment.